Atricure, INC Form 4 insider transactions

Karen Prange, a Director of AtriCure, Inc., sold 3,564 shares of common stock on August 5, 2026 for $38.80 per share.

Maggie Yuen, a Director of AtriCure, Inc., sold 3,500 shares of common stock on August 5, 2026 for $38.42 per share.

Michael H Carrel, President, CEO, & Director and a Director of AtriCure, Inc., reported multiple transactions in common stock on July 30, 2026.

Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., sold 6,000 shares of common stock on July 28, 2026 for $38.88 per share.

Sven Wehrwein, a Director of AtriCure, Inc., sold 25,000 shares of common stock on July 28, 2026 for $37.84 per share.

Justin J Noznesky, Chief Mktg & Strategy Officer of AtriCure, Inc., sold 6,182 shares of common stock on July 29, 2026 for $38.80 per share.

AtriCure, Inc. CEO Michael H. Carrel acquired company shares through the Employee Stock Purchase Plan on June 30, 2026.

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, acquired 636 shares of common stock through the company's Employee Stock Purchase Plan.

AtriCure's Chief Legal Officer, Karl S. Dahlquist, acquired company stock through the Employee Stock Purchase Plan.

AtriCure, Inc. reports that Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company's Employee Stock Purchase Plan.

AtriCure, Inc. Chief Technical Officer Salvatore Privitera acquired 636 shares of common stock through the company's Employee Stock Purchase Plan.

AtriCure, Inc. Director Karen Prange reported the sale of 3,000 shares of common stock at a weighted average price of $28.65.

Director Karen Prange acquired 6,144 shares of AtriCure, Inc. common stock through a Restricted Stock Award.

Director Deborah H. Telman acquired 6,144 shares of AtriCure common stock through a Restricted Stock Award.

Director Maggie Yuen acquired 6,144 shares of AtriCure, Inc. common stock through a Restricted Stock Award.

Director Shlomo Nachman acquired 6,144 shares of AtriCure, Inc. common stock through a Restricted Stock Award.

Director B. Kristine Johnson acquired 6,144 shares of AtriCure, Inc. common stock through a Restricted Stock Award.

Regina E. Groves, a Director at AtriCure, Inc., acquired 6,144 shares of common stock through a Restricted Stock Award.

Director Sven Wehrwein acquired 6,144 shares of common stock in AtriCure, Inc. through a Restricted Stock Award.

Director Robert S. White acquired 6,144 shares of AtriCure, Inc. common stock through a Restricted Stock Award.

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, reported the sale of 5,000 shares of common stock on May 15, 2026.

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, sold 5,000 shares of common stock for approximately $149,150 through a pre-arranged trading plan.

AtriCure Director Robert S. White exercised 10,000 non-qualified stock options at $14.99 per share, increasing his direct common stock holdings to 122,174 shares.

AtriCure's Chief Operating Officer, Douglas J. Seith, acquired 257 shares of common stock through the company's Employee Stock Purchase Plan at a price of $27.37 per share.

AtriCure's President and CEO, Michael H. Carrel, reported a charitable gift of 4,000 shares of the company's common stock.

AtriCure Director Sven Wehrwein exercised stock options and subsequently sold the acquired common stock on November 24 and 25, 2025.

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, reported a planned sale of 5,166 common shares under a Rule 10b5-1 plan.

AtriCure Director Maggie Yuen reported the sale of 3,000 shares of common stock at a weighted average price of $35.72 per share on November 21, 2025, executed under a Rule 10b5-1 trading plan.

AtriCure's President and CEO, Michael H. Carrel, reported a charitable gift of 6,000 shares of common stock on November 13, 2025.

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 3,000 shares of common stock for a weighted average price of $36.30 per share.